<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35310349</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">2452-199X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>14</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>Bioactive materials</Title>
          <ISOAbbreviation>Bioact Mater</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Felodipine enhances aminoglycosides efficacy against implant infections caused by methicillin-resistant <i>Staphylococcus aureus</i>, persisters and biofilms.</ArticleTitle>
        <Pagination>
          <StartPage>272</StartPage>
          <EndPage>289</EndPage>
          <MedlinePgn>272-289</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bioactmat.2021.11.019</ELocationID>
        <Abstract>
          <AbstractText>Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA), biofilms, and persisters are three major factors leading to recurrent and recalcitrant implant infections. Although antibiotics are still the primary treatment for chronic implant infections in clinical, only few drugs are effective in clearing persisters and formed biofilms. Here, felodipine, a dihydropyridine calcium channel blocker, was reported for the first time to have antibacterial effects against MRSA, biofilm, and persisters. Even after continuous exposure to sub-lethal concentrations of felodipine, bacteria are less likely to develop resistance. Besides, low doses of felodipine enhances the antibacterial activity of gentamicin by inhibiting the expression of protein associated with aminoglycoside resistance (aacA-aphD). Next, biofilm eradication test and persisters killing assay suggested felodipine has an excellent bactericidal effect against formed biofilms and persisters. Furthermore, the result of protein profiling, and quantitative metabonomics analysis indicated felodipine reduce MRSA virulence (agrABC), biofilm formation and TCA cycle. Then, molecular docking showed felodipine inhibit the growth of persisters by binding to the H pocket of ClpP protease, which could lead to substantial protein degradation. Furthermore, murine infection models suggested felodipine in combination with gentamicin alleviate bacterial burden and inflammatory response. In conclusion, low dose of felodipine might be a promising agent for biomaterial delivery to enhance aminoglycosides efficacy against implant infections caused by MRSA, biofilm, and persisters.</AbstractText>
          <CopyrightInformation>© 2021 The Authors.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Shutao</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Bone and Joint Surgery, Department of Orthopedics, Renji Hospital, Shanghai Jiaotong University School of Medicine, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qu</LastName>
            <ForeName>Xinhua</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Bone and Joint Surgery, Department of Orthopedics, Renji Hospital, Shanghai Jiaotong University School of Medicine, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiao</LastName>
            <ForeName>Juyang</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Bone and Joint Surgery, Department of Orthopedics, Renji Hospital, Shanghai Jiaotong University School of Medicine, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Haozheng</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Bone and Joint Surgery, Department of Orthopedics, Renji Hospital, Shanghai Jiaotong University School of Medicine, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Minqi</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Bone and Joint Surgery, Department of Orthopedics, Renji Hospital, Shanghai Jiaotong University School of Medicine, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>You</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Bone and Joint Surgery, Department of Orthopedics, Renji Hospital, Shanghai Jiaotong University School of Medicine, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Hongtao</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medical Science and Engineering, Beihang University, Beijing, 100191, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yuan</LastName>
            <ForeName>Weien</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Engineering Research Center of Cell &amp; Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yue</LastName>
            <ForeName>Bing</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Bone and Joint Surgery, Department of Orthopedics, Renji Hospital, Shanghai Jiaotong University School of Medicine, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Bioact Mater</MedlineTA>
        <NlmUniqueID>101685294</NlmUniqueID>
        <ISSNLinking>2452-199X</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Aminoglycosides</Keyword>
        <Keyword MajorTopicYN="N">Felodipine</Keyword>
        <Keyword MajorTopicYN="N">Implant infection</Keyword>
        <Keyword MajorTopicYN="N">Methicillin-resistant Staphylococcus aureus</Keyword>
        <Keyword MajorTopicYN="N">Persisters</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>21</Day>
          <Hour>9</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35310349</ArticleId>
        <ArticleId IdType="pmc">PMC8897655</ArticleId>
        <ArticleId IdType="doi">10.1016/j.bioactmat.2021.11.019</ArticleId>
        <ArticleId IdType="pii">S2452-199X(21)00540-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Magill S.S., Edwards J.R., Bamberg W., Beldavs Z.G., Dumyati G., Kainer M.A., Lynfield R., Maloney M., McAllister-Hollod L., Nadle J., Ray S.M., Thompson D.L., Wilson L.E., Fridkin S.K. I. Emerging infections Program healthcare-associated, T. Antimicrobial use prevalence survey, multistate point-prevalence survey of health care-associated infections. N. Engl. J. Med. 2014;370(13):1198–1208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4648343</ArticleId>
            <ArticleId IdType="pubmed">24670166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Darouiche R.O. Treatment of infections associated with surgical implants. N. Engl. J. Med. 2004;350(14):1422–1429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15070792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davies D. Understanding biofilm resistance to antibacterial agents. Nat. Rev. Drug Discov. 2003;2(2):114–122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12563302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pulido L., Ghanem E., Joshi A., Purtill J.J., Parvizi J. Periprosthetic joint infection: the incidence, timing, and predisposing factors. Clin. Orthop. Relat. Res. 2008;466(7):1710–1715.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2505241</ArticleId>
            <ArticleId IdType="pubmed">18421542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turner N.A., Sharma-Kuinkel B.K., Maskarinec S.A., Eichenberger E.M., Shah P.P., Carugati M., Holland T.L., Fowler V.G., Jr. Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research. Nat. Rev. Microbiol. 2019;17(4):203–218.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6939889</ArticleId>
            <ArticleId IdType="pubmed">30737488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y., Jia Y., Yang K., Li R., Xiao X., Zhu K., Wang Z. Metformin restores tetracyclines susceptibility against multidrug resistant bacteria. Adv. Sci. 2020;7(12):1902227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7312304</ArticleId>
            <ArticleId IdType="pubmed">32596101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim W., Zou G., Hari T.P.A., Wilt I.K., Zhu W., Galle N., Faizi H.A., Hendricks G.L., Tori K., Pan W., Huang X., Steele A.D., Csatary E.E., Dekarske M.M., Rosen J.L., Ribeiro N.Q., Lee K., Port J., Fuchs B.B., Vlahovska P.M., Wuest W.M., Gao H., Ausubel F.M., Mylonakis E. A selective membrane-targeting repurposed antibiotic with activity against persistent methicillin-resistant Staphylococcus aureus. Proc. Natl. Acad. Sci. U. S. A. 2019;116(33):16529–16534.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6697817</ArticleId>
            <ArticleId IdType="pubmed">31358625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stewart P.S., Franklin M.J. Physiological heterogeneity in biofilms. Nat. Rev. Microbiol. 2008;6(3):199–210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18264116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olsen I. Biofilm-specific antibiotic tolerance and resistance. Eur. J. Clin. Microbiol. Infect. Dis. 2015;34(5):877–886.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25630538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fisher R.A., Gollan B., Helaine S. Persistent bacterial infections and persister cells. Nat. Rev. Microbiol. 2017;15(8):453–464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28529326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Defraine V., Fauvart M., Michiels J. Fighting bacterial persistence: current and emerging anti-persister strategies and therapeutics. Drug Resist. Updates. 2018;38:12–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29857815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ventola C.L. The antibiotic resistance crisis: part 2: management strategies and new agents. P T. 2015;40(5):344–352.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4422635</ArticleId>
            <ArticleId IdType="pubmed">25987823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu J., Li Y., Zhang Y., Liang Y., Zheng Y., Li Z., Zhu S., Li C., Cui Z., Wu S. An engineered pseudo-macrophage for rapid treatment of bacteria-infected osteomyelitis via microwave-excited anti-infection and immunoregulation. Adv. Mater. 2021;33(41)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34396595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeng J.K., Wang Y.T., Sun Z.Y., Chang H.S., Cao M., Zhao J., Lin K.L., Xie Y.Z. A novel biocompatible PDA/IR820/DAP coating for antibiotic/photodynamic/photothermal triple therapy to inhibit and eliminate Staphylococcus aureus bio film. Chem. Eng. J. 2020;394</Citation>
        </Reference>
        <Reference>
          <Citation>Brown D. Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void? Nat. Rev. Drug Discov. 2015;14(12):821–832.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26493767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Payne D.J., Gwynn M.N., Holmes D.J., Pompliano D.L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 2007;6(1):29–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17159923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng W., Sun W., Simeonov A. Drug repurposing screens and synergistic drug-combinations for infectious diseases. Br. J. Pharmacol. 2018;175(2):181–191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5758396</ArticleId>
            <ArticleId IdType="pubmed">28685814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Law G.L., Tisoncik-Go J., Korth M.J., Katze M.G. Drug repurposing: a better approach for infectious disease drug discovery? Curr. Opin. Immunol. 2013;25(5):588–592.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4015799</ArticleId>
            <ArticleId IdType="pubmed">24011665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tyers M., Wright G.D. Drug combinations: a strategy to extend the life of antibiotics in the 21st century. Nat. Rev. Microbiol. 2019;17(3):141–155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30683887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Todd P.A., Faulds D. Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders. Drugs. 1992;44(2):251–277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1382018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bansal A.B., Khandelwal G.  2021. Felodipine, StatPearls. Treasure Island (FL)</Citation>
        </Reference>
        <Reference>
          <Citation>Siddiqi F.H., Menzies F.M., Lopez A., Stamatakou E., Karabiyik C., Ureshino R., Ricketts T., Jimenez-Sanchez M., Esteban M.A., Lai L., Tortorella M.D., Luo Z., Liu H., Metzakopian E., Fernandes H.J.R., Bassett A., Karran E., Miller B.L., Fleming A., Rubinsztein D.C. Felodipine induces autophagy in mouse brains with pharmacokinetics amenable to repurposing. Nat. Commun. 2019;10(1):1817.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6472390</ArticleId>
            <ArticleId IdType="pubmed">31000720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>CLSI . Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. eleventh ed. 2018. </Citation>
        </Reference>
        <Reference>
          <Citation>Blaskovich M.A.T., Hansford K.A., Gong Y., Butler M.S., Muldoon C., Huang J.X., Ramu S., Silva A.B., Cheng M., Kavanagh A.M., Ziora Z., Premraj R., Lindahl F., Bradford T.A., Lee J.C., Karoli T., Pelingon R., Edwards D.J., Amado M., Elliott A.G., Phetsang W., Daud N.H., Deecke J.E., Sidjabat H.E., Ramaologa S., Zuegg J., Betley J.R., Beevers A.P.G., Smith R.A.G., Roberts J.A., Paterson D.L., Cooper M.A. Protein-inspired antibiotics active against vancomycin- and daptomycin-resistant bacteria. Nat. Commun. 2018;9(1):22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5750218</ArticleId>
            <ArticleId IdType="pubmed">29295973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim W., Zhu W., Hendricks G.L., Van Tyne D., Steele A.D., Keohane C.E., Fricke N., Conery A.L., Shen S., Pan W., Lee K., Rajamuthiah R., Fuchs B.B., Vlahovska P.M., Wuest W.M., Gilmore M.S., Gao H., Ausubel F.M., Mylonakis E. A new class of synthetic retinoid antibiotics effective against bacterial persisters. Nature. 2018;556(7699):103–107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6462414</ArticleId>
            <ArticleId IdType="pubmed">29590091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ng T.W., Chan W.L., Lai K.M. Influence of membrane fatty acid composition and fluidity on airborne survival of Escherichia coli. Appl. Microbiol. Biotechnol. 2018;102(7):3327–3336.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29450618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sandoval R., Leiser J., Molitoris B.A. Aminoglycoside antibiotics traffic to the Golgi complex in LLC-PK1 cells. J. Am. Soc. Nephrol. 1998;9(2):167–174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9527392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang S., Tang H., Wang Y., Nie B., Yang H., Yuan W., Qu X., Yue B. Antibacterial and antibiofilm effects of flufenamic acid against methicillin-resistant Staphylococcus aureus. Pharmacol. Res. 2020;160:105067.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32650057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le P., Kunold E., Macsics R., Rox K., Jennings M.C., Ugur I., Reinecke M., Chaves-Moreno D., Hackl M.W., Fetzer C., Mandl F.A.M., Lehmann J., Korotkov V.S., Hacker S.M., Kuster B., Antes I., Pieper D.H., Rohde M., Wuest W.M., Medina E., Sieber S.A. Repurposing human kinase inhibitors to create an antibiotic active against drug-resistant Staphylococcus aureus, persisters and biofilms. Nat. Chem. 2020;12(2):145–158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6994260</ArticleId>
            <ArticleId IdType="pubmed">31844194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim W., Zou G., Pan W., Fricke N., Faizi H.A., Kim S.M., Khader R., Li S., Lee K., Escorba I., Vlahovska P.M., Gao H., Ausubel F.M., Mylonakis E. The neutrally charged diarylurea compound PQ401 kills antibiotic-resistant and antibiotic-tolerant Staphylococcus aureus. mBio. 2020;11(3)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7327171</ArticleId>
            <ArticleId IdType="pubmed">32605985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng W., Fu T., Zhang Z., Jiang X., Xie J., Sun H., Hu P., Ren H., Zhou P., Liu Q., Long Q. L-lysine potentiates aminoglycosides against Acinetobacter baumannii via regulation of proton motive force and antibiotics uptake. Emerg. Microb. Infect. 2020;9(1):639–650.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7144275</ArticleId>
            <ArticleId IdType="pubmed">32192413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song K., Huang M., Shi Q., Du T., Cao Y. Cultivation and identification of rat bone marrow-derived mesenchymal stem cells. Mol. Med. Rep. 2014;10(2):755–760.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24859847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang S., Qu X., Tang H., Wang Y., Yang H., Yuan W., Yue B. Diclofenac resensitizes methicillin-resistant Staphylococcus aureus to beta-lactams and prevents implant infections. Adv. Sci. 2021;8(13):2100681.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8261494</ArticleId>
            <ArticleId IdType="pubmed">34258168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qu X., Yang H., Jia B., Wang M., Yue B., Zheng Y., Dai K. Zinc alloy-based bone internal fixation screw with antibacterial and anti-osteolytic properties. Bioact. Mater. 2021;6(12):4607–4624.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8141820</ArticleId>
            <ArticleId IdType="pubmed">34095620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan L.C., Chaili S., Filler S.G., Barr K., Wang H., Kupferwasser D., Edwards J.E., Jr., Xiong Y.Q., Ibrahim A.S., Miller L.S., Schmidt C.S., Hennessey J.P., Jr., Yeaman M.R. Nonredundant roles of interleukin-17a (IL-17A) and IL-22 in murine host defense against cutaneous and hematogenous infection due to methicillin-resistant Staphylococcus aureus. Infect. Immun. 2015;83(11):4427–4437.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4598415</ArticleId>
            <ArticleId IdType="pubmed">26351278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yeaman M.R., Filler S.G., Chaili S., Barr K., Wang H., Kupferwasser D., Hennessey J.P., Jr., Fu Y., Schmidt C.S., Edwards J.E., Jr., Xiong Y.Q., Ibrahim A.S. Mechanisms of NDV-3 vaccine efficacy in MRSA skin versus invasive infection. Proc. Natl. Acad. Sci. U. S. A. 2014;111(51):E5555–E5563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4280579</ArticleId>
            <ArticleId IdType="pubmed">25489065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang M., Li H., Yang Y., Yuan K., Zhou F., Liu H., Zhou Q., Yang S., Tang T. A 3D-bioprinted scaffold with doxycycline-controlled BMP2-expressing cells for inducing bone regeneration and inhibiting bacterial infection. Bioact. Mater. 2021;6(5):1318–1329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7658329</ArticleId>
            <ArticleId IdType="pubmed">33210025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bunce C., Wheeler L., Reed G., Musser J., Barg N. Murine model of cutaneous infection with gram-positive cocci. Infect. Immun. 1992;60(7):2636–2640.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC257214</ArticleId>
            <ArticleId IdType="pubmed">1612733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thompson J.M., Saini V., Ashbaugh A.G., Miller R.J., Ordonez A.A., Ortines R.V., Wang Y., Sterling R.S., Jain S.K., Miller L.S. Oral-only linezolid-rifampin is highly effective compared with other antibiotics for periprosthetic joint infection study of a mouse model. J. Bone Jt. Surg. Am. 2017;99(8):656–665.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6181281</ArticleId>
            <ArticleId IdType="pubmed">28419033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang S., Li H., Tang H., Huo S., Nie B., Qu X., Yue B. Felodipine blocks osteoclast differentiation and ameliorates estrogen-dependent bone loss in mice by modulating p38 signaling pathway. Exp. Cell Res. 2020;387(2):111800.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31877305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y., Teng W., Zhang Z., Zhou X., Ye Y., Lin P., Liu A., Wu Y., Li B., Zhang C., Yang X., Li W., Yu X., Gou Z., Ye Z. A trilogy antimicrobial strategy for multiple infections of orthopedic implants throughout their life cycle. Bioact. Mater. 2021;6(7):1853–1866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7732879</ArticleId>
            <ArticleId IdType="pubmed">33336116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao C., Zhu W., Xiang Y., Zhu Y., Shen J., Liu X., Wu S., Cheung K.M.C., Yeung K.W.K. Enhanced near-infrared photocatalytic eradication of MRSA biofilms and osseointegration using oxide perovskite-based P-N heterojunction. Adv. Sci. 2021;8(15)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8336500</ArticleId>
            <ArticleId IdType="pubmed">34145798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gillaspy A.F., Hickmon S.G., Skinner R.A., Thomas J.R., Nelson C.L., Smeltzer M.S. Role of the accessory gene regulator (agr) in pathogenesis of staphylococcal osteomyelitis. Infect. Immun. 1995;63(9):3373–3380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC173464</ArticleId>
            <ArticleId IdType="pubmed">7642265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes D., Karlen A. Discovery and preclinical development of new antibiotics. Ups. J. Med. Sci. 2014;119(2):162–169.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4034554</ArticleId>
            <ArticleId IdType="pubmed">24646082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossolini G.M., Arena F., Pecile P., Pollini S. Update on the antibiotic resistance crisis. Curr. Opin. Pharmacol. 2014;18:56–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25254623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garvin K.L., Hinrichs S.H., Urban J.A. Emerging antibiotic-resistant bacteria. Their treatment in total joint arthroplasty. Clin. Orthop. Relat. Res. 1999;369:110–123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10611866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Howe R.A., Bowker K.E., Walsh T.R., Feest T.G., MacGowan A.P. Vancomycin-resistant Staphylococcus aureus. Lancet. 1998;351(9102):602.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9492814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luppens S.B., Reij M.W., van der Heijden R.W., Rombouts F.M., Abee T. Development of a standard test to assess the resistance of Staphylococcus aureus biofilm cells to disinfectants. Appl. Environ. Microbiol. 2002;68(9):4194–4200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC124130</ArticleId>
            <ArticleId IdType="pubmed">12200265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kapadia B.H., Berg R.A., Daley J.A., Fritz J., Bhave A., Mont M.A. Periprosthetic joint infection. Lancet. 2016;387(10016):386–394.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26135702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Namba R.S., Prentice H.A., Paxton E.W., Hinman A.D., Kelly M.P. Commercially prepared antibiotic-loaded bone cement and infection risk following cemented primary total knee arthroplasty. J. Bone Jt. Surg. Am. 2020;102(22):1930–1938.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32826555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campoccia D., Montanaro L., von Eiff C., Pirini V., Ravaioli S., Becker K., Arciola C.R. Cluster analysis of ribotyping profiles of Staphylococcus epidermidis isolates recovered from foreign body-associated orthopedic infections. J. Biomed. Mater. Res. 2009;88(3):664–672.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18496868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campoccia D., Baldassarri L., Pirini V., Ravaioli S., Montanaro L., Arciola C.R. Molecular epidemiology of Staphylococcus aureus from implant orthopaedic infections: ribotypes, agr polymorphism, leukocidal toxins and antibiotic resistance. Biomaterials. 2008;29(30):4108–4116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18676012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hajipour M.J., Saei A.A., Walker E.D., Conley B., Omidi Y., Lee K.B., Mahmoudi M. Nanotechnology for targeted detection and removal of bacteria: opportunities and challenges. Adv. Sci. 2021;8(21)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8564466</ArticleId>
            <ArticleId IdType="pubmed">34558234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mayorga-Martinez C.C., Zelenka J., Grmela J., Michalkova H., Ruml T., Mares J., Pumera M. Swarming aqua sperm micromotors for active bacterial biofilms removal in confined spaces. Adv. Sci. 2021;8(19)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8498868</ArticleId>
            <ArticleId IdType="pubmed">34369099</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
